Court rules against experimental drugs for terminally ill

Share this article:

Terminally ill patients should not be permitted to obtain experimental drugs, a U.S. Court of Appeals for the District of Columbia Circuit has ruled, siding with the Food and Drug Administration.

In a reversal of a May 2006 ruling by a smaller panel of the court, the appeals court ruled that terminally ill patients do not have the right to gain access to unapproved prescription drugs even if they are potentially lifesaving.

The Abigail Alliance for Better Access to Developmental Drugs and the Washington Legal Foundation filed a lawsuit asking the Food and Drug Administration to approve experimental medications that appear effective and allow for their sale and distribution to terminally ill patients. The FDA, response, stated that such a waiver would lead to unacceptable risk. The current ruling came after the FDA appealed a three-judge panel's decision.

The opinion is at http://www.cadc.uscourts.gov.
Share this article:

More in News

Nursing home antipsychotic use has dipped nearly 19% under national effort, latest figures show

Nursing home antipsychotic use has dipped nearly 19% ...

The percent of long-stay nursing home residents receiving antipsychotic medication has decreased 18.8% under a nationwide initiative that started in 2012.

Jimmo succeeds in getting Medicare coverage, two years after landmark case ended

Glenda Jimmo has reached a settlement with the federal government and will finally receive Medicare coverage for claims that were denied in 2007, which led her to file a class-action lawsuit over the so-called "improvement standard."

Breier named new CEO at Kindred

Breier named new CEO at Kindred

Kindred Healthcare announced Thursday that it has chosen a new top executive to lead its push toward creating a mammoth national brand. Benjamin A. Breier, the company's current president and ...